Press release archive - GSK
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
Press releases | GSK US
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2
Oct 9, 2024 · GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on...
Health Canada approves GSK's Ojjaara for myelofibrosis in …
2 days ago · Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is indicated for use in patients with intermediate or high-risk primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF.
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
GSK announces cap of $35 per month on U.S. patient out-of …
GSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease (COPD) medicines,* the most prescribed portfolio of inhalers in the U.S. GSK is taking this action as part of its longstanding commitment to improving access to respiratory medici...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease.
GlaxoSmithKline News | GSK News - NewsNow
NewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications.
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
LONDON, Feb 15 (Reuters) - GSK (GSK.L) said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory...
GSK lifts annual forecasts again, powered by strong vaccine launch
Nov 1 (Reuters) - GSK (GSK.L) raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its respiratory syncytial virus (RSV) vaccine in the...
- Some results have been removed